“Bullish on Sun Pharma for the next six months, recommending a buy between ₹1,930 and ₹1,970 with a target of ₹2,250 and a stop loss at ₹1,900. The stock has broken out from a two-year consolidation, indicating a resumption of its long-term uptrend, with momentum indicators supporting further upside.”